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NEWS AND PERSPECTIVES
The clinically prognostic impact of tumor-infiltrat-
ing lymphocytes (TIL) has been a longstanding
debate. TIL have been used to demonstrate how
the host immune system recognizes and attempts
to eliminate malignant cells.1 In spite of their tena-
cious presence in the antitumor tug-of-war, cancer
remains one of the major causes of human death.
In adoptive immunity against a variety of human
cancers, TIL have been recognized widely to be
relevant to patient outcome. In cases in which TIL
are involved in patient outcome in cancer, T lym-
phocytes are recognized as the main effectors of
the antitumor immune response.1–5 Previously, we
have demonstrated that human cancer cells might
alter the functional composition of antitumor 
effector cells, including CD8+ cytotoxic T cells,
within the tumor milieu.1–3 We have defined pre-
dominant Th2/Tc2 patterns of cytokine expression
in a subset of CD3+CD8+ T cell in human cancer.2
We have illustrated further that certain cancer-
derived mediators are responsible for the im-
munosuppressive conditions of TIL in human
cancer, and are associated highly with prognostic
significance clinically.3,4 The regulation of the 
cytolytic function, especially natural killer 
(NK)-like cytotoxicity, of CD3+CD8+ cytotoxic 
T lymphocytes in human cancer has been strati-
fied, which signifies the possibility of further
cancer immunotherapy.3–5 Moreover, recent stud-
ies have revealed that a subset of CD4+ T cells, 
referred to as CD4+CD25+ regulatory T (Treg)
cells, might accumulate in the cancer microenvi-
ronment and restrain tumor-specific T-cell re-
sponses, thereby hindering tumor rejection.
Generally, Treg cells are characterized by ele-
vated surface CD25 and intracellular Forkhead
P3 (FoxP3) expressions.6 These cells exist in no-
ticeably higher proportions within TIL and/or 
regional lymph node lymphocytes of patients
with cancer.6,7 The presence of infiltrating CD4+
CD25+ Treg cells is controversial in anti-cancer
immunity and even destructive to host defense
against the tumor. This is despite the abundance
of effector T lymphocytes, including CD8+ T
cells and non-regulatory CD4+ T-helper cells, in
cancer patients. It has been shown that Treg 
cells enriched in FoxP3, glucocorticoid-induced
tumor necrosis factor receptor, and cytotoxic 
T-lymphocyte-associated antigen-4 potentially
suppress the peripheral effector T cells.6
Increasing evidence has shown that elevated
proportions of CD4+ Treg cells are present in
various types of human cancer and thus abrogate
antitumor immunity. Essentially, tumor-specific
Treg cells require ligand-specific activation and
cell-to-cell contact to exert their destructive activity
on tumor-specific effector cells, which includes
decreased cytotoxicity, proliferation, and Th1 cy-
tokine secrection.6,7 Recent studies have linked
Toll-like receptor (TLR) signaling to the functional
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control of Treg cells. Treg cells can modulate mul-
tiple cell types, including T cells, B cells, dendritic
cells (DC) and NK cells, by using diverse suppres-
sor mechanisms. By now, certain factors that regu-
late Treg cell proliferation and function, including
TLR ligands, have also been identified. It has been
shown that TLR-8 signaling might regulate directly
the suppressive function of CD4+ and CD8+ Treg
cells.8 Studies also have demonstrated that tumor
cells can recruit these Treg cells to hold back an-
titumor immunity in the tumor microenviron-
ment, which consequently limits the efficiency 
of possible cancer immunotherapy.6–8
It is thought that TLR-mediated recognition of
specific structures of invading pathogens initiates
innate as well as adaptive immune responses
through DC. In cancer, Treg cells seem to induce
immune tolerance by suppressing host immune
responses against self or non-self antigens. Tumor-
specific Treg cells recently have been identified
and characterized, which has provided com-
pelling evidence that such antigen-specific Treg
cells can induce tumor-specific local immune
tolerance.9 Innovative evidence has suggested
that TLR signaling may directly regulate the sup-
pressive function of Treg cells. Linkage of TLR sig-
naling to the functional control of Treg cells may
shift the balance between CD4+ T-helper and
Treg cells, thus improving the outcome of cancer
immunotherapy.10
Strategies for modulating the effect of Treg
cells on current immunotherapeutic and cancer
targeting regimens have been proposed.11–13
Recent evidence has suggested that TLR signaling
may regulate the suppressive function of CD4+
CD25+ Treg cells in local and systemic immune
responses. TLR signaling has been proposed to
shift the balance between CD4+ T-helper and Treg
cells, and subsequently influence the outcome 
of the immune response.11 For possible im-
munotherapy, this Treg immunomodulation
pathway may have potential applications in the
treatment of graft rejection, autoimmune diseases,
infectious diseases and cancer.12
In cancer immunotherapy, an increasing num-
ber of studies of Treg cells in patients with cancer
stress the role of these cells in associated disease
progression.11–13 Essentially, Treg cells express
certain TLRs. The activation and suppressor func-
tion of Treg cells are modulated by the binding
of the respective TLR ligands. Similar to the double-
edged nature of anti-cancer immunity, TLR lig-
ands are proposed to induce suppression or
enhancement of Treg cells. Furthermore, recent
studies have shown that mature DC can override
Treg-mediated suppression both in vitro and 
in vivo.12,13 Naturally occurring Treg cells suppress
T-cell responses by cell-contact-dependent mech-
anisms, whereas induced regulatory cells, includ-
ing the T inducible regulatory type 1 cells, secrete
inhibitory cytokines such as transforming growth
factor-β and interleukin (IL)-10.14 The interplay
between Treg and antigen-responsive T cells is
modulated by DC.14,15 manipulation of mature
DC that are activated through TLR recognition
receptors can also induce the secretion of pro-
inflammatory cytokines, including IL-6, and thus
render responder T cells refractory to the sup-
pressive effect of Treg cells.13
On the contrary, multiple immunosuppres-
sive mechanisms subsist, noticeably diminish
the anticancer immune responses and dampen
the clinical application of current immunothera-
peutic regimens. Modulation of Treg cells sheds
new light on the reversal of cancer-mediated
immunosuppression before immunotherapy 
can be applied successfully. Several studies have
indicated that Treg cells inhibit effective antitu-
mor immune responses and that removal of Treg
cells facilitates tumor elimination.12–15 Clinically,
numerous studies of Treg cells in cancer patients
also have indicated the key role of Treg cells in
associated cancer progression.14,15 Indeed, much
evidence has shown that the Treg cells can shape
the immune response to tumors, hold back effec-
tive tumor immuno-surveillance, and thus pro-
mote cancer invasion and metastasis.12–15
Recently, active immunotherapy with therapeutic
cancer vaccines has now progressed from the lab-
oratory to clinical applications. Advanced in-
sights into the distinctiveness of the regulatory
elements of the immune system, especially Treg
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cells, can show additional possibilities to en-
hance anticancer immunity and thereby increase
the chance of cancer patient survival.14–16
In addition, a number of molecular regulators
of T-cell-receptor signaling, either positive or neg-
ative, have been proposed in the context of Treg
cell maturation. Among these, major histocompat-
ibility complex class II modulation, self-ligands
expressed by epithelial cells, and thymic stromal
lymphopoietin seem to have synergistic roles.17
Additionally, Treg cells can express FoxP3 as a tran-
scriptional repressor of IL-2 and other cytokines,
and thus retain the anergic and suppressor function
of these cells. Treg cells play an important role in
the control of autoimmunity, therefore, therapeutic
strategies have focused on the enhancement of Treg
cell function in specific autoimmune diseases.17
Conclusion
Strategies for therapeutic targeting of Treg cells
and their potential effect on current cancer im-
munotherapy are under intensive investigation.
By now, certain factors that regulate Treg prolifera-
tion and function, including TLR ligands, have
been identified and proposed as potential im-
munotherapeutic regimens. Exploration of the
mechanisms of Treg cell modulation gives rise 
to opportunities for controlling the function of
Treg cell subsets, and thus gives scope for effective
immunotherapy of cancer.
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